BioSpace News Archive

Today, AnaBios announced a Research Collaboration Agreement (RCA) with the U.S. Food and Drug Administration (FDA) to study adult human primary cardiomyocytes as a reference for cellular properties and drug-induced effects on cardiac function.

CytRx Corporation (OTCQB: CYTR), a biopharmaceutical research and development company specializing principally in oncology and neurodegenerative diseases, today announced that effective immediately, Mr. Eric Curtis , President and Chief Operating Officer of CytRx Corporation and President and CEO of Centurion BioPharma Corporation, is

Rivet’s modern solution improves healthcare revenue cycle management by providing up-front treatment costs and easing friction in patient payments.

Developer of Nerivio™, a Drug-Free Therapeutic Wearable for the Acute Treatment of Migraine,

More than two-thirds of healthcare leaders have seen quality improve, but budget is the No. 1 reason they won’t invest

CrowdOptic and National Bioskills Laboratories confirmed the organizations’ ability to provide remote training for physicians and employees at enterprises affected by the travel restrictions surrounding the recent COVID-19 outbreak.

George Health will receive $35 million from three major investment partners to develop drug treatments and technologies for world’s biggest killers

Medical professionals from Texas, and 17 additional states, recently completed the first Laser Therapy Certification Course sponsored by Aspen Laser Systems, LLC, a medical device company and emerging global leader in innovative photomedicine technology, in conjunction with the ChiroSymposium 2020 event held at the Gaylord Resort in Grapevine, Texas, February 21-23, 2020.

Agenus Inc., an immuno-oncology company with an extensive pipeline of agents designed to activate immune response to cancers, announced the triggering of a $15.1M milestone payment from HealthCare Royalty Partners based on net sales of GlaxoSmithKline’s Shingrix vaccine exceeding $2.0B in 2019.

aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced the underwriters of its previously announced public offering of common stock have fully exercised their over-allotment option resulting in the issuance of an additional 635,294 shares of common stock. The option was granted in connection with the public offering of 4,235,